Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock

Zacks' analysis highlights Zimmer Biomet (ZBH) as a strong value stock, assigning it a Zacks #2 (Buy) Rank and a B rating for both its VGM and Value Style Scores, underpinned by an attractive forward P/E of 12.95. The company has seen positive analyst revisions, with 10 analysts raising fiscal 2025 earnings estimates, increasing the consensus to $8.11 per share, and maintaining a historical average earnings surprise of +1.8%. This combination of robust analytical ratings and favorable earnings outlook positions ZBH as a notable consideration for investors.

Analysis

Zimmer Biomet (ZBH) is presented as a compelling value investment based on the Zacks quantitative rating system. The company holds a Zacks #2 (Buy) rank, supported by a 'B' grade for both its composite VGM Score and its specific Value Style Score. This value proposition is substantiated by an attractive forward P/E ratio of 12.95. The bullish outlook is further reinforced by positive momentum in analyst sentiment, evidenced by 10 upward earnings estimate revisions for fiscal 2025 over the past 60 days. These revisions have collectively lifted the Zacks Consensus Estimate for fiscal 2025 earnings per share by $0.16 to $8.11. Additionally, ZBH has demonstrated a consistent ability to exceed market expectations, historically delivering an average positive earnings surprise of 1.8%.

Key Decisions for Investors

• Value-oriented investors should note ZBH's forward P/E of 12.95, which, combined with strong analyst ratings, suggests potential undervaluation relative to its earnings outlook.
• The positive trend in earnings revisions, with the fiscal 2025 consensus EPS rising to $8.11, serves as a key forward-looking indicator that may warrant initiating or adding to a position.
• Investors should consider that the stock's profile, characterized by favorable valuation, positive estimate revisions, and a history of earnings beats, aligns well with criteria for a long-term holding in a diversified healthcare portfolio.